NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD
29.6
-0.73 (-2.41%)
The current stock price of RXST is 29.6 USD. In the past month the price decreased by -8.67%. In the past year, price decreased by -45.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 29.9 | 45.13B | ||
COO | COOPER COS INC/THE | 23.91 | 17.66B | ||
ALGN | ALIGN TECHNOLOGY INC | 20.39 | 14.22B | ||
SOLV | SOLVENTUM CORP | 17.55 | 12.61B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 30.7 | 6.01B | ||
BLCO | BAUSCH + LOMB CORP | 25.4 | 5.55B | ||
LNTH | LANTHEUS HOLDINGS INC | 11.27 | 5.44B | ||
ICUI | ICU MEDICAL INC | 27.69 | 3.85B | ||
XRAY | DENTSPLY SIRONA INC | 10.14 | 3.73B | ||
HAE | HAEMONETICS CORP/MASS | 14.9 | 3.17B | ||
NEOG | NEOGEN CORP | 25.1 | 2.18B | ||
UFPT | UFP TECHNOLOGIES INC | 36.31 | 1.95B |
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 374 full-time employees. The company went IPO on 2021-07-30. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. The company designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
RXSIGHT INC
100 Columbia Street, Suite 120
Aliso Viejo CALIFORNIA US
CEO: Ron Kurtz
Employees: 374
Company Website: https://www.rxsight.com/
Investor Relations: https://investors.rxsight.com/
Phone: 19495217822
The current stock price of RXST is 29.6 USD. The price decreased by -2.41% in the last trading session.
The exchange symbol of RXSIGHT INC is RXST and it is listed on the Nasdaq exchange.
RXST stock is listed on the Nasdaq exchange.
16 analysts have analysed RXST and the average price target is 53.14 USD. This implies a price increase of 79.53% is expected in the next year compared to the current price of 29.6. Check the RXSIGHT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RXSIGHT INC (RXST) has a market capitalization of 1.19B USD. This makes RXST a Small Cap stock.
RXSIGHT INC (RXST) currently has 374 employees.
RXSIGHT INC (RXST) has a support level at 29.59 and a resistance level at 30.51. Check the full technical report for a detailed analysis of RXST support and resistance levels.
The Revenue of RXSIGHT INC (RXST) is expected to grow by 58.78% in the next year. Check the estimates tab for more information on the RXST EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RXST does not pay a dividend.
RXSIGHT INC (RXST) will report earnings on 2025-02-25, after the market close.
RXSIGHT INC (RXST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).
The outstanding short interest for RXSIGHT INC (RXST) is 6.07% of its float. Check the ownership tab for more information on the RXST short interest.
ChartMill assigns a fundamental rating of 4 / 10 to RXST. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RXST reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 50.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9.89% | ||
ROE | -11.07% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to RXST. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 46.55% and a revenue growth 58.78% for RXST